Skip to main content
. 2011 Jan;13(1):74–84. doi: 10.1016/j.jmoldx.2010.11.010

Figure 2.

Figure 2

Lung cancer triplex sizing assay. The triplex sizing assay was established to detect simultaneously EGFR exon 19 deletions, EGFR exon 20 insertions, and HER2 20 insertions. A: Examples of results with known positive controls. 1, human genomic DNA was used as a wild-type control (peaks are indicated by dashed lines); 2, H1650 cell line DNA showed a 15-nucleotide deletion in EGFR exon 19 (arrow); 3, DNA from a previously characterized lung adenocarcinoma sample showed a three-nucleotide insertion in EGFR exon 20 (arrow); 4, H1781 cell line DNA showed a homozygous three-nucleotide insertion in HER2 exon 20 (arrow). B: Sensitivity assays. Samples carrying the known mutations were diluted with human genomic DNA in ratios of 100%, 25%, 12.5%, 6.25%, 3.125%, 1.56%, and 0%. Mixtures were then used to perform the sizing assay. The arrows indicate the mutation peaks at the lowest dilution rate.